ASSESSMENT OF THE EFFECT OF RS2230806 ALLELIC VARIANT IN THE <i>ABCA1</i> GENE ON THE LIPID-LOWERING EFFECTS OF ATORVASTATIN IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Objective: to evaluate the effect of rs2230806 variant in the ABCA1 gene on lipid and apolipoprotein (apo)A-I and apoB levels after the atorvastatin treatment in patients with heterozygous familial hypercholesterolemia (FH). Material and methods. The study included 83 patients with FH according to the British clinical SBR-criteria of the disease, all patients received atorvastatin at a dose of 40 mg/day for 3 months.Genotypingthe rs2230806 polymorphism was determined by «real time» polymerase chain reaction (PCR) using adjacent samples and melting reaction products after PCR. Total cholesterol (TC) and triglycerides (TG) were determined by a unified enzymatic method, high - density lipoproteins (HDL) and low - density lipoproteins (LDL) - by a direct homogeneous method, apoproteins - by immunoturbidimetric method. Results. Carriers of allelic variant were 52.9 % of patients (with one allele in 31.4 %, with two in 21.4 %). We revealed a difference in the change from the initial values of TC (-40.2 % vs. -34.4 %; p = 0.041), LDL (-50.8 % vs. -44 %; p = 0.041) and apoB (-48 % vs. -38.3 %; p = 0.02) with greater response to atorvastatin in homozygous carriers (genotype A/A) compared with heterozygous (genotype G/A) ones. The selective analysis depending on the sex and genotype rs2230806 among male carriers of allelic variant revealed a significant increase in the levels of HDL and apoAI by 10.6 % and 15.5 %, respectively, while in patients without polymorphism these lipid parameters decreased (by 3.8 % and 3.9 %, respectively). Conclusion. The variant rs2230806 in the ABCA1 gene was associated with a significant lipid-lowering effect of atorvastatin, and also increased the levels of apoA-containing plasma lipoproteins in male patients with FH.